Pan-genotypic regimen for HCV effective in eight weeks for the majority of patients1
1. Puoti M. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293-300
Per segnalazione di eventi avversi
Servizio di Famacovigilanza
Tel: +39 06 92892 6666
E-Mail: farmacovigilanza@abbvie.com
Servizio Infomed riservato ai medici e ai farmacisti per le richieste di informazioni mediche
Il servizio InfoMed gestirà esclusivamente le richieste sui nostri prodotti e relative aree terapeutiche
E-Mail: abbvieitalyinfomed@abbvie.com
Attenzione: questo indirizzo di posta elettronica è riservato a medici e farmacisti
per richieste scientifiche sui nostri prodotti.
Reference the most recent version of the SmPC, scanning the QR Code.
The continually updated version of the SmPC is also available on the website https://rcpabbvie.it/mav
Ex-factory price (VAT EXCLUDED): € 14,000
Retail price (VAT EXCLUDED): € 23,105.60
Reimbursement class: A
Classification for supply: medicinal products subject to limited medical prescription, with single refills, sold to the public by prescription from hospital centers or specialists: infectious disease specialists, gastroenterologists, internists (RNRL)
Stored at AIFA on 09/25/2019 - Code IT-MAVI-190076